Paloma Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-15,600
Closed -$1.26M 895
2023
Q4
$1.26M Sell
15,600
-27,100
-63% -$2.11M 0.05% 370
2023
Q3
$3.2M Buy
+42,700
New +$3.28M 0.11% 159
2019
Q4
Sell
-32,900
Closed -$2.08M 2288
2019
Q3
$2.08M Buy
+32,900
New +$2.15M 0.04% 412
2019
Q2
Sell
-68,400
Closed -$4.45M 1906
2019
Q1
$4.45M Buy
+68,400
New +$4.55M 0.11% 199
2018
Q2
Sell
-61,500
Closed -$4.64M 1842
2018
Q1
$4.64M Sell
61,500
-39,300
-39% -$3.12M 0.07% 228
2017
Q4
$7.22M Sell
100,800
-11,200
-10% -$851K 0.1% 174
2017
Q3
$9.07M Sell
112,000
-221,300
-66% -$16.9M 0.12% 138
2017
Q2
$23.6M Sell
333,300
-95,600
-22% -$6.36M 0.28% 37
2017
Q1
$29.1M Sell
428,900
-487,700
-53% -$34.3M 0.35% 35
2016
Q4
$65.6M Buy
916,600
+244,500
+36% +$18.2M 0.64% 13
2016
Q3
$53.2M Sell
672,100
-796,000
-54% -$64.7M 0.67% 22
2016
Q2
$122M Buy
1,468,100
+917,500
+167% +$81.4M 1.35% 10
2016
Q1
$50.6M Buy
550,600
+379,200
+221% +$34.2M 0.83% 12
2015
Q4
$17.3M Sell
171,400
-165,900
-49% -$17.3M 0.46% 27
2015
Q3
$33.1M Sell
337,300
-52,700
-14% -$5.85M 0.77% 16
2015
Q2
$45.7M Buy
+390,000
New +$42.6M 0.88% 11

Other funds holding GILD

Paloma Partners's GILD Position: Q3 2024 in Review

Paloma Partners sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 6,700 shares — an estimated $460K sold.

Paloma Partners first reported a position in GILD in Q2 2013 and held it in 33 quarters. The position peaked at $31.4M in Q2 2016. 1,718 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

  • Paloma Partners reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 6,700 Gilead Sciences shares in Q3 2024, an estimated $460K.
  • Paloma Partners first reported a position in Gilead Sciences in Q2 2013 and held it in 33 quarters.
  • Paloma Partners's Gilead Sciences position peaked at $31.4M in Q2 2016.
  • 1,718 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.